hyperlipidemia

(redirected from primary hyperlipidemia)
Also found in: Dictionary, Thesaurus.

hyperlipidemia

 [hi″per-lip″i-de´me-ah]
elevated concentrations of any or all of the lipids in the blood. Called also hyperlipemia and lipemia.

hy·per·lip·id·e·mi·a

(hī'pĕr-lip'i-dē'mē-ă),
Elevated levels of lipids in the blood plasma. There are several types of hyperlipemia. One is associated with a deficiency of δ-aminoadipic semialdehyde synthase.

hyperlipidemia

/hy·per·lip·id·emia/ (-lip″ĭ-de´me-ah) elevated concentrations of any or all of the lipids in the plasma, including hypertriglyceridemia, hypercholesterolemia, etc.hyperlipide´mic
combined hyperlipidemia  a generic designation for a hyperlipidemia in which several classes of lipids are elevated; usually used to denote the phenotype of a type II-b hyperlipoproteinemia.
familial combined hyperlipidemia  an inherited disorder of lipoprotein metabolism manifested in adulthood as hypercholesterolemia, hypertriglyceridemia, or a combination, with elevated plasma apolipoprotein B and premature coronary atherosclerosis.
mixed hyperlipidemia  see under hyperlipemia.
remnant hyperlipidemia  a form in which the accumulated lipoproteins are normally transient intermediates, chylomicron remnants, and intermediate-density lipoproteins; a generic descriptor for the type III hyperlipoproteinemia phenotype.

hyperlipidemia

(hī′pər-lĭp′ĭ-dē′mē-ə, -lī′pĭ-)
n.
An excess of fats or lipids in the blood. Also called hyperlipemia.

hyperlipidemia

[-lip′idē′mē·ə]
Etymology: Gk, hyper + lipos, fat, haima, blood
an excess of lipids, including glycolipids, lipoproteins, and phospholipids, in the plasma. Also spelled hyperlipidaemia. See also antilipidemic.

hyperlipidemia

An ↑ of circulating lipids–fatty acids, TGs, and cholesterol, often linked to ↑ lipoproteins–hyperlipoproteinemia and/or ↓ degradative enzymes–eg, lipoprotein lipase. See Acquired hyperlipidemia, Familial combined hyperlipidemia.
Hyperlipidemia
Primary Dyslipidemia intimately linked to CAD
Secondary
Secondary hypercholesterolemia, seen in acute intermittent porphyria, cholestasis, hypothyroidism and pregnancy.
Secondary hypertriglyceridemia, seen in DM, acute alcohol intoxication, acute pancreatitis, gout, gram-negative sepsis, glycogen storage disease I, oral contraceptive use.
Combined hypercholesterolemia & hypertriglyceridemia, seen in nephrotic syndrome, chronic renal failure, corticosteroid therapy and immunosuppression.
Note: 30-40% of the population is sensitive to dietary cholesterol and ↑ dietary cholesterol may ↑ cholesterol in the circulation

li·pe·mi·a

(li-pē'mē-ă)
The presence of an abnormally high concentration of lipids in the circulating blood.
Synonym(s): hyperlipidemia, hyperlipoidemia, lipidemia, lipoidemia, lipaemia.
[lipid + G. haima, blood]

Hyperlipidemia

A general term for elevated concentrations of any or all of the lipids in the plasma.

hy·per·lip·id·e·mi·a

(hī'pĕr-lip'i-dē'mē-ă)
Elevated levels of lipids in the blood plasma.
Synonym(s): hyperlipidaemia.

hyperlipidemia,

n an excess of lipids in the plasma, including the glycolipids, lipoproteins, and phospholipids.

hyperlipidemia

a general term for elevated concentrations of any or all of the lipids in the plasma. See also hyperlipoproteinemia.

postprandial hyperlipidemia
a normal increase following ingestion of food.
primary hyperlipidemia
caused by decreased activity of lipoprotein lipase, it occurs in miniature Schnauzer dogs.
secondary hyperlipidemia
may occur in association with diabetes mellitus, hypothyroidism, pancreatitis, hyperadrenocorticism, cholestatic liver disease and nephrotic syndrome.
References in periodicals archive ?
Welchol[R] is indicated as an adjunct to diet and exercise to reduce elevated LDL-C in patients with primary hyperlipidemia as monotherapy, or in combination with a statin.
In clinical studies, administration of ezetimibe, 50 mg/day to 15 healthy subjects for up to 14 days, or 40 mg/day to 18 patients with primary hyperlipidemia for up to 56 days, was generally well tolerated.
Five multicenter, double-blind studies conducted with either VYTORIN or coadministered ezetimibe and simvastatin equivalent to VYTORIN in patients with primary hyperlipidemia are reported: two were comparisons with simvastatin, two were comparisons with atorvastatin, and one was a comparison with rosuvastatin.
Response to VYTORIN in Patients with Primary Hyperlipidemia
Fenoglide([R]) is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, triglycerides, and Apo B, and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia.
WELCHOL[R] is indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia (Fredrickson Type IIa) as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin), reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy, and improve glycemic control in adults with type 2 diabetes mellitus.
LIVALO([R]) (pitavastatin), a potent HMG-CoA reductase inhibitor, was approved by the FDA in August 2009 for the treatment of primary hyperlipidemia and mixed dyslipidemia.
In a multicenter, double-blind, 6-week study, 2959 patients with primary hyperlipidemia, who had not met their NCEP ATP III target LDL-C goal, were randomized to one of six treatment groups: VYTORIN (10/20, 10/40, or 10/80) or rosuvastatin (10 mg, 20 mg, or 40 mg).
Reduce elevated total-C, LDL-C, and Apo B in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin) (1.
In 10 double-blind, placebo-controlled clinical trials, 2396 patients with primary hyperlipidemia (age range 9-86 years, 50% women, 90% Caucasians, 5% Blacks, 3% Hispanics, 2% Asians) and elevated LDL-C were treated with ZETIA 10 mg/day for a median treatment duration of 12 weeks (range 0 to 39 weeks).
Focusing on patient evaluation, mechanism of disease, and diagnosis, this reference for professionals and advanced students draws on a rich collection of color and b&w photos, explanatory diagrams, and other medical imaging to explore the range of primary hyperlipidemias and related gene and protein structures for important mutations.
In this exciting new volume, the authors draw upon a rich collection of visual material to explore the full range of primary hyperlipidemias.

Full browser ?